Table 1.
Clinicopathologic patient characteristics
| Patients, no. (%) |
|||
|---|---|---|---|
| Characteristic | BRCA1/2 PV (n = 224) | No mutation (n = 1989) | P value |
| Age, y | |||
| Median (range) | 41 (23–84) | 46 (19–83) | <.001 |
| ≤40 | 108 (48.2) | 577 (29) | <.001 |
| >40 | 116(51.8) | 1412 (71) | |
| Race | |||
| Black /African American | 35 (15.6) | 266 (13.4) | .075 |
| Hispanic/Latino | 47 (21) | 342 (17.2) | |
| White | 124 (55.4) | 1271 (63.9) | |
| Asian or American Indian/Alaska Native | 18(8) | 110 (5.5) | |
| Menopausal status | |||
| Premenopausal | 62 (27.7) | 760 (38.2) | .002 |
| Postmenopausal* | 162 (72.3) | 1229 (61.8) | |
| Clinical T stage | |||
| Unknown† | 4(1.8) | 35 (1.8) | .036 |
| T0/Tis | 1 (0.5) | 11 (0.6) | |
| T1 | 57 (25.9) | 704 (36) | |
| T2 | 110(50) | 807 (41.3) | |
| T3 | 35 (15.9) | 266 (13.6) | |
| T4 | 17 (7.7) | 166 (8.5) | |
| Clinical nodal status | |||
| Unknown† | 4(1.8) | 35 (1.8) | <.001 |
| N0 | 143(65) | 993 (50.8) | |
| N+ | 77 (35) | 961 (49.2) | |
| Overall clinical stage | |||
| I | 40 (17.9) | 554 (27.9) | .005 |
| II | 110(49.1) | 890 (44.7) | |
| III | 74 (33) | 545 (27.4) | |
| Pathologic T stage | |||
| T0/Tis | 57 (25.4) | 356 (17.9) | .037 |
| T1 | 86 (38.4) | 866 (43.5) | |
| T2 | 60 (26.8) | 504 (25.3) | |
| T3 | 17 (7.6) | 227 (11.4) | |
| T4 | 4(1.8) | 36 (1.8) | |
| Pathologic nodal status | |||
| N0 | 119 (53.1) | 1056 (53.1) | .993 |
| N+ | 105 (46.9) | 933 (46.9) | |
| Overall pathologic stage | |||
| 0 | 46 (20.5) | 292 (14.7) | .063 |
| I | 55 (24.6) | 605 (30.4) | |
| II | 80 (35.7) | 676 (34) | |
| III | 43 (19.2) | 416 (20.9) | |
| Hormone receptor status | |||
| Unknown† | 7(3.1) | 10 (0.5) | <.001 |
| Negative | 93 (42.9) | 517 (26.1) | |
| Positive | 124 (57.1) | 1462 (73.9) | |
| Her2-neu status | |||
| Unknown† | 17 (7.6) | 65 (3.3) | <.001 |
| Negative | 192 (92.8) | 1557 (80.9) | |
| Positive | 15 (7.2) | 367 (19.1) | |
| TNBC status | |||
| Unknown† | 13 (5.8) | 22 (1.1) | <.001 |
| Non-TNBC | 126 (59.7) | 1605 (81.6) | |
| TNBC | 85 (40.3) | 362 (18.4) | |
| Nuclear grade Unknown† | 7 (3.1) | 18 (0.9) | <.001 |
| I-II | 54 (24.9) | 903 (45.8) | |
| III | 163 (75.1) | 1068 (54.2) | |
| LVSI | |||
| Unknown† | 2 (0.9) | 22 (1.1) | .770 |
| Yes | 63 (28.4) | 540 (27.5) | |
| No | 159 (71.6) | 1427 (72.5) | |
| Year of surgery ≤2000 | 25 11.2) | 139 (7) | .038 |
| 2001–2010 | 89 39.7) | 745 (37.5) | |
| 2011–2017 | 110 (49.1) | 1105 (55.6) | |
| Type of definitive surgery | |||
| Breast conserving surgery | 72 (32.1) | 1077 (54.1) | <.001 |
| Mastectomy | 152 (67.9) | 912 (45.9) | |
| Positive nodes, no. | |||
| <10 | 211 (94.2) | 1856 (93.3) | .614 |
| ≥10 | 13 (5.8) | 133 (6.7) | |
| Nodes removed, no. | |||
| Unknown* | 1 (0.5) | 3 (0.2) | .014 |
| <10 | 75 (33.6) | 837 (42.1) | |
| ≥10 | 148 (66.4) | 1149 (57.9) | |
| Radiation type | |||
| Breast | 54 (24.1) | 748 (37.6) | <.001 |
| Breast + RNI | 18 (8.0) | 329 (16.5) | |
| CW only | 5 (2.2) | 12 (0.6) | |
| CW + RNI | 147 (65.6) | 900 (45.2) | |
| Neoadjuvant chemotherapy | |||
| No | 72 (32.1) | 930 (46.8) | <.001 |
| Yes | 152 (67.9) | 1059 (53.2) | |
| Any chemotherapy | |||
| Yes | 202 (90.2) | 1667 (83.8) | .013 |
| No | 22 (9.8) | 322 (16.2) | |
| Adjuvant hormone therapy | |||
| Unknown† | 1 (0.5) | 0 | <.001 |
| Yes | 105 (47.1) | 1372 (69.0) | |
| No | 118 (52.9) | 617 (31.0) | |
| BSO | |||
| Yes | 64 (28.6) | 228 (11.5) | <.001 |
| No or > 1 y from breast surgery | 160 (71.4) | 1761 (88.5) | |
| Synchronous contralateral breast cancer | |||
| Yes | 19 (8.5) | 78 (3.9) | .002 |
| No | 205 (91.5) | 1911 (96.1) | |
Abbreviations: BSO = bilateral salpingo-oophorectomy; CW = chest wall; LVSI = lymphovascular space invasion; PV = pathogenic variant; RNI = regional nodal irradiation; TNBC = triple negative breast cancer.
*
Patients who had a prophylactic or therapeutic BSO at the time of diagnosis were considered postmenopausal.
†
Patients with unknown status were omitted from statistical analyses.